ERBB2 and breast carcinoma: The lack of detailed records regarding chemotherapy regimens and response rates, as well as genetic background data, may introduce confounding variables that hinder a comprehensive understanding of chemotherapy regimens and treatment effects on HER2-Low breast cancer patients and potential genetic influences on treatment response and disease progression.